Form Type:  SC 13G/A
Filing Date:  2/12/2020 
CIK:  0001293971 
Address:  60 BINNEY STREET 
City, State, Zip:  CAMBRIDGE, Massachusetts 02142 
Telephone:  339-499-9300 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
-0.03 (-0.05%)  
Trade Time: 
Jun 03  
Market Cap: 
Trade BLUE now with 

© 2020  
Description of Business
We are a biotechnology company committed to researching, developing, and commercializing potentially transformative gene therapies for severe genetic diseases and cancer. We have built an integrated product platform with broad therapeutic potential in a variety of indications based on our lentiviral gene addition platform, gene editing and cancer immunotherapy capabilities. We believe that gene therapy for severe genetic diseases has the potential to change the way patients living with these diseases are treated by addressing the underlying genetic defect that is the cause of their disease, rather than offering treatments that only address their symptoms. Our gene therapy programs include LentiGlobin for ?-thalassemia; LentiGlobin for sickle cell disease, or SCD; and Lenti-D for cerebral adrenoleukodystrophy, or CALD.
Register and access this filing in: